What is HC Wainwright's Estimate for INKT FY2026 Earnings?

MiNK Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS estimate for MiNK Therapeutics to a loss of $2.29 per share from a previously forecast loss of $2.58. Its estimate is less pessimistic than the current consensus loss of $2.53 per share.
  • HC Wainwright maintained a Buy rating and $38 price target. The firm also forecasts losses of $0.59 per share in Q4 2026 and $0.64 per share in each of FY2027 and FY2028.
  • MiNK reported a quarterly loss of $0.50 per share, beating analyst expectations of a $0.66 loss; revenue of $0.20 million also exceeded the $0.07 million estimate.
  • Five stocks to consider instead of MiNK Therapeutics.

MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Equities research analysts at HC Wainwright increased their FY2026 earnings estimates for MiNK Therapeutics in a research report issued on Wednesday, November 11th. HC Wainwright analyst M. Keller now anticipates that the company will post earnings of ($2.29) per share for the year, up from their prior forecast of ($2.58). HC Wainwright currently has a "Buy" rating and a $38.00 target price on the stock. The consensus estimate for MiNK Therapeutics' current full-year earnings is ($2.53) per share. HC Wainwright also issued estimates for MiNK Therapeutics' Q4 2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($0.64) EPS.

A number of other research firms have also issued reports on INKT. B. Riley Financial restated a "buy" rating and issued a $50.00 target price (up from $43.00) on shares of MiNK Therapeutics in a report on Wednesday, October 21st. Zacks Research downgraded MiNK Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, MiNK Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $44.00.

Check Out Our Latest Analysis on INKT

MiNK Therapeutics Trading Down 6.8%

NASDAQ INKT opened at $9.53 on Friday. The firm's 50 day moving average price is $11.14 and its two-hundred day moving average price is $11.21. MiNK Therapeutics has a twelve month low of $8.48 and a twelve month high of $16.93.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last issued its quarterly earnings results on Wednesday, November 11th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.16. The firm had revenue of $0.20 million during the quarter, compared to analysts' expectations of $0.07 million.

Insider Buying and Selling at MiNK Therapeutics

In other news, CEO Jennifer Buell sold 6,938 shares of the stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the sale, the chief executive officer directly owned 74,195 shares of the company's stock, valued at $783,499.20. This represents a 8.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 20.40% of the stock is owned by corporate insiders.

MiNK Therapeutics Company Profile

(Get Free Report)

MiNK Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company's platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses. MiNK's lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.

Featured Articles

Earnings History and Estimates for MiNK Therapeutics (NASDAQ:INKT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MiNK Therapeutics Right Now?

Before you consider MiNK Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiNK Therapeutics wasn't on the list.

While MiNK Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines